Genome Editing Market Report 2024: Technology Licensing Deals are Driving the Overall Partnership Activity - Global Industry Trends and Forecasts 2023-2035

News provided by

Feb 07, 2024, 13:30 ET

DUBLIN, Feb. 7, 2024 /PRNewswire/ -- The "Global Genome Editing Market, 2023-2035: Focus on Technology, Industry Trends and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The global genome editing market size for technologies is estimated to be worth USD 3.5 billion in 2023 and is expected to grow at CAGR of 12.6% during the forecast period (2023-2035).

The report features an extensive study of the current market landscape, market size and future opportunities associated with the genome editing market, during the given forecast period. Further, the genome editing market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the genome editing market analysis are briefly discussed below.

Genome Editing Market: Current Market Landscape

The genome editing market landscape is concentrated with the presence of over 110 genome editing companies (very large, large, mid-sized and small companies). Of these, 57% of the companies were established post-2016, indicating significant start-up activity in the genome editing industry. Examples of companies (established in 2022 and 2023, in alphabetical order) include Akribion Genomics, CorriXR Therapeutics, Couragene, GENETAGUS, GrittGene Therapeutics, Nvelop Therapeutics, Primera Therapeutics and SE Therapeutics.

Moreover, some of the stakeholders engaged in genome editing market also offer gene editing services in order to optimize the use of their resources and augment their revenue generation opportunities. In Europe, Horizon Discovery (also known as Revvity) emerged as the only genetic engineering company whose business model operates via in-house development of gene edited therapies, licensing of its Pin-pointT base editing platform and through genome editing service capabilities.

CRISPR/Cas9 are the Most Sought Genome Editing Tools

Of all the genome editing tools, CRISPR technology, specifically, CRISPR-Cas9 has emerged as the leading genetic engineering technique developed by the stakeholders in the gene editing market. Recently, the domain has witnessed a paradigm shift from conventional CRISPR technology to base editing and prime editing techniques. These novel tools are aimed to improve the long-term safety and efficiency of gene delivery. In this market report, the analyst has captured all the genome editing tools (including CRISPR technology) developed by genome editing companies that are relevant to drug discovery, regenerative medicine and diagnostic applications.

North America to Hold the Largest Market Share

Over the past few years, there has been a steady increase in the genome editing companies offering various gene editing technologies. Of these, majority of the technology developers are based in North America. It is worth noting that Intellia Therapeutics, Mammoth Biosciences and Metagenomi (arranged in alphabetical order) are the mid-sized companies based in North America that operate as base editing companies.

Technology Licensing Deals are Driving the Overall Partnership Activity

Several stakeholders have been forging alliances with other industry / non-industry players in the genome editing market for different purposes, including technology licensing, research and development, product licensing and product development. It is worth highlighting that, since 2018, over 250 strategic partnerships have been inked by the technology developers in the genome engineering market. Up lately, the pharmaceutical companies have been engaged in the acquisition of other market players engaged in the genome editing industry in order to expand their capabilities and build a comprehensive pipeline. In March 2023, WuXi AppTec acquired OXGENE and enhanced its capabilities for the development of cell and gene therapies. Earlier, in February 2023, Ensoma acquired Twelve Bio, a gene editing company working in area of the CRISPR medicines. As more drug developers license genome editing technology for evaluation, the market growth is expected to witness favorable market growth during the forecast period.

Key Topics Covered:

1. PREFACE

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. TECHNOLOGY LANDSCAPE
6.1. Chapter Overview
6.2. Genome Editing: Technology Landscape
6.3. Genome Editing: Technology Developer Landscape

7. TECHNOLOGY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Technology Competitiveness Analysis

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Arcturus Therapeutics
8.3. Beam Therapeutics
8.4. Caribou Biosciences
8.5. Century Therapeutics
8.6. CRISPR Therapeutics
8.7. Editas Medicine
8.8. Graphite Bio
8.9. Intellia Therapeutics
8.10. Prime Medicine
8.11. Vor Biopharma
8.12. Other Leading Players
8.12.1. Avectas
8.12.2. Bio-Sourcing
8.12.3. Edigene
8.12.4. Flash Therapeutics
8.12.5. Fortgen
8.12.6. G+FLAS Life Sciences
8.12.7. Ntrans Technologies
8.12.8. OXGENE
8.12.9. Revvity
8.12.10. TargetGene Biotechnologies
8.12.11. ZeClinics

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Genome Editing Technologies: Partnerships and Collaborations

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Genome Editing Domain: Patent Analysis
10.4. Genome Editing Domain: Patent Benchmarking Analysis
10.5. Patent Valuation Analysis

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Genome Editing Domain: Funding and Investment Analysis

12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

13. GENOME EDITING TECHNOLOGIES MARKET
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Genome Editing Technologies Market, Forecasted Estimates (2023-2035)

14. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. CRISPR-Cas System: Forecasted Estimates (2023-2035)
14.4. TALENs: Forecasted Estimates (2023-2035)
14.5. Meganucleases: Forecasted Estimates (2023-2035)
14.6. ZFNs: Forecasted Estimates (2023-2035)
14.7. Other Techniques: Forecasted Estimates (2023-2035)

15. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Cell Therapies: Forecasted Estimates (2023-2035)
15.4. Gene Therapies: Forecasted Estimates (2023-2035)
15.5. Other Therapies: Forecasted Estimates (2023-2035)

16. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Gene Knock-Out Approaches: Forecasted Estimates (2023-2035)
16.4. Gene Knock-In Approaches: Forecasted Estimates (2023-2035)

17. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Ex-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.4. In-Vivo Delivery Methods: Forecasted Estimates (2023-2035)

18. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Viral Vectors: Forecasted Estimates (2023-2035)
18.4. Non-Viral Vectors: Forecasted Estimates (2023-2035)

19. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Drug Discovery and Development: Forecasted Estimates (2023-2035)
19.4. Diagnostics: Forecasted Estimates (2023-2035)

20. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
20.4. Academic and Research Institutes: Forecasted Estimates (2023-2035)

21. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Forecasted Estimates (2023-2035)
21.4. Europe: Forecasted Estimates (2023-2035)
21.5. Asia-Pacific: Forecasted Estimates (2023-2035)

22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Milestone Payments: Forecasted Estimates (2023-2035)
22.4. Upfront Payments: Forecasted Estimates (2023-2035)

23. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS
23.1. Chapter Overview
23.2. Leading Industry Players

Companies Mentioned

AbbVie
Abcam
Acrigen Biosciences
Acuitas Therapeutics
Affini-T Therapeutics
Aju IB Investments
Akribion Genomics
Aldevron
Alexion Pharmaceuticals
Alia Therapeutics
Allogene Therapeutics
Ally Bridge Group
Almirall
Altium Capital
Amgen Ventures
Andreessen Horowitz
AnGes
Ankarys Therapeutics
ANLBIO
APEIRON Biologics
Apellis Pharmaceuticals
Applied StemCell
Arbor Biotechnologies
ARCH Venture Partners
Arctoris
Arcturus Therapeutics
Arix Bioscience
Armistice Capital
Avoro Ventures
Axcelead
Axxam
Bain Capital Life Sciences
Bayer
Beam Therapeutics
Bio Palette
Bio-Sourcing
Biocytogen
Biogen
Bioluminescence Ventures
Bioneer
Blink Therapeutics
BlueRock Therapeutics
BOP Capital
Boston Children's Hospital
Boxer Capital
BRAIN Biotech
BrainXell
Branca Bunus
BrightPath Biotherapeutics
Bristol-Myers Squibb
C4U
C4X Discovery
CaaS Capital
Cabaletta Bio
Canaccord Genuity
Capsida Biotherapeutics
Capstan Therapeutics
Caribou Biosciences
Cartherics
CasCure Therapeutics
Casdin Capital
Caszyme
Catalent
CCRM
CD Capital
Cellecta
Cellectis
CellFE
Celularity
Century Therapeutics
CF Foundation
CHA Biotech
CHA Research Institute
Charcot-Marie-Tooth Association
China Life Healthcare Fund
ChristianaCare
Cimeio Therapeutics
Clairvoyant Ventures
CorriXR Therapeutics
Cosmo Bio
Cota Capital
Couragene
CPE
Creative Biogene
Curamys
Curia
CyGenica
Cystic Fibrosis Foundation
Cytosurge
Cytovia Therapeutics
D1 Capital Partners
Daiichi Sankyo
Danaher
DCI Partners
Decheng Capital
DefiniGEN
Delos Capital
Dynamk Capital
EcoR1 Capital
EdiGene
Editas Medicine
eGenesis
Elaia Partners
Eledon Pharmaceuticals
Eli Lilly
Emerson Collective
Empirica
Ennovation Ventures
Ensoma
EPIQ Capital Group
ERS Genomics
ETP Ventures
Eurofins
EV Biologics
Evercrisp Biosciences
Evotec
Excision BioTherapeutics
Exothera
F-Prime Capital
Farallon Capital
FASMAC
Feldan Therapeutics
Flash Therapeutics
Foresite Capital
Fortgen
Future Fields
G+FLAS Life Sciences
GC Cell
GEcoll Biomedical
GEMoaB
GenAhead Bio
GeneLancet Biosciences
Genentech
GENETAGUS
Genethon
Genexine
GenKOre
Gilead Sciences
GL Ventures
GordonMD Global Investments
Graphite Bio
GreatPoint Ventures
Green Cross LabCell
Green Sands
Gritstone Oncology
GrittGene Therapeutics
GSK Consumer Healthcare
HBM Healthcare Investments
HebeCell
Heights Capital
Hera Biolabs
Hercules Capital
Hitachi Ventures
Hunterian Medicine
IDG Capital
iECURE
Illumina
Immatics
Immunochina
Inceptor Bio
Incisive Genetics
Infinome Biosciences
Inhibrx
Innovation Agency
Inscripta
Intellia Therapeutics
Intima Bioscience
Invus
Ionis Pharmaceuticals
Iovance Biotherapeutics
Irving Investors
JAFCO
Janssen Biotech
Jasper Therapeutics
Kite Ventures
Kiwoom Investment
Kleiner Perkins
KRYSP-R
KSQ Therapeutics
Kyverna Therapeutics
Lake Bleu Capital
Lapam Capital
Leaps by Bayer
Lepton Pharmaceuticals
LG Chem
Life Edit Therapeutics
LifeSci Venture Partners
Lilly Asia Venture
LogicBio Therapeutics
Longmen Capital
Lonza
Loyal Valley Capital
Lyell Immunopharma
LYFE Capital
MacHall Group
Macrogen
Magenta Therapeutics
Makana Therapeutics
Mammoth Biosciences
Matrix Partners China
Maxcyte
Mayfield
Mayo Clinic
Mercia
Merck
Metagenomi
Micro CRISPR
MidCap Financial
Mind the Byte
Mizuho Securities
Modalis Therapeutics
Moderna
Mogrify
Moogene Medi
Morningside Ventures
Myeloid Therapeutics
Merieux Developpement
Nanjing Bioheng Biotech
National Science Foundation
Nephrogen
Neukio Biotherapeutics
Newpath Partners
Newtyn Management
Nippon Gene
Nkarta
Noile-Immune Biotech
Novartis
Novo Holdings
Novo Nordisk
Ntrans Technologies
NUVISAN ICB
Nvelop Therapeutics
Oak HC/FT
Octagon Capital
ONK Therapeutics
Orbital Therapeutics
Otsuka Pharmaceutical
Outpace Bio
Oxford Finance
OXGENE
Paladin Capital
PanCELLa
Pangen Biotech
Panmure Gordon
Pantherna Therapeutics
Pencil Biosciences
Perceptive Advisors
Pfizer
PFM Health Sciences
Phen Vista
Pluristyx
Polaris Partners
Polyplus-transfection
Precision BioSciences
Prevail Therapeutics
Prime Medicine
Primera Therapeutics
Primordial Genetics
ProBioGen
Promega
Prorenata Biotech
QUIDDITAS Therapeutics
RA Capital Management
Recipharm
ReCode Therapeutics
Recombinetics
Red Tree Venture Capital
Redmile Group
Reforgene Medicine
Rege Nephro
Regeneron
Resilience
Rewrite Therapeutics
Ridgeback Capital Investments
Rock Springs Capital
RTW Investments
Samsara BioCapital
Sana Biotechnology
Sandhill Therapeutics
Sangamo Therapeutics
Sanofi
Santa Cruz Biotechnology
Sanzheng Health Investment
Scottish Enterprise
Scribe Therapeutics
SDIC Venture Capital
SE Therapeutics
Setsuro Tech
Shanghai BDgene Technology
Shoreline Biosciences
Silicon Valley Bank
Simcere Pharmaceuticals
SJ Investment Partners
SML Genetree
Sofinnova Partners
Solana Biosciences
Songhe Capital
SOSV
SparingVision
Sphere Fluidics
Spotlight Therapeutics
SpringWorks Therapeutics
Starfish Innovations
Stellate DNA
STIC Ventures
T&R Biofab
T-MAXIMUM Biotech
Takara Bio
Takeda Pharmaceuticals
TargetGene Biotechnologies
Taros Chemicals
TCG Crossover
TCR Therapeutics
TechLife Capital
Temasek
Teneobio
The Wells Investment
Thermo Fisher Scientific
Tiziana Life Sciences
Tofflon
ToolGen
TPG Capital
Transomic Technologies
TransViragen
Trentino Invest
Tsinghua Holdings Capital
Twist Bioscience
TxCell
Versant Ventures
Vertex Pharmaceuticals
Verve Therapeutics
Vesigen Therapeutics
ViaCyte
Vida Ventures
Vingroup
VirEdit Biosciences
Viromer Transfection
Vivlion
Vor Biopharma
Voyager Therapeutics
WuXi AppTec
Yuansheng Venture Capital
ZeClinics

For more information about this report visit https://www.researchandmarkets.com/r/m3w674

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets